Immunotherapy breaches low-sugar dieting of tumor Treg cells
- PMID: 33951469
- DOI: 10.1016/j.cmet.2021.04.010
Immunotherapy breaches low-sugar dieting of tumor Treg cells
Abstract
Glycolysis supports effector T cell function but is detrimental to the immunosuppressive activity of regulatory T cells. In a recent issue of Nature, two papers address a role for glucose and lactate availability within the tumor microenvironment for the balance of pro- and anti-tumoral effects of T cells and the efficacy of neoadjuvant cancer immunotherapy.
Copyright © 2021 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests A.Y.R. is an SAB member of and holds equity or stock options in Sonoma Biotherapeutic, Surface Oncology, RAPT Therapeutics, and Vedanta Biosciences. He is an SAB member of BioInvent and holds IP rights for therapeutic Treg cell depleting antibodies.
Comment on
-
CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumours.Nature. 2021 Mar;591(7851):652-658. doi: 10.1038/s41586-021-03326-4. Epub 2021 Feb 15. Nature. 2021. PMID: 33588426 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
